arrow
S

Susan Halabi

Duke University Medical Center
H指数:81
被引数:3.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success☆

癌症预防药物的随机III期临床试验:一项系统综述和试验成功的预测<a class="anchor anchor-primary" href="#fn1" name="bfn1" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fn1"><span class="anchor-text-container"><span class="anchor-text"><sup>☆</sup></span></span></a>

2026-09-090
OAAI
AI-based augmentation of oncology clinical trials

基于人工智能的肿瘤学临床试验增强

2026-08-070
PRE
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)

雄激素受体剪接变体7的细胞质与核定位作为预测转移性去势抵抗性前列腺癌中雄激素受体通路抑制剂获益的指标(PROPHECY试验)

2026-04-020
PRE
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)

风险分层与治疗获益:一项预测在探索多西他赛试验中转移性去势敏感型前列腺癌患者总生存期的模型(STOPCAP合作项目)

2026-02-180
PRE
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS

先前通过根治性前列腺切除术或放疗进行的局部治疗对达鲁柳胺治疗的ARAMIS患者的疗效和生活质量的影响

2025-12-260
OAAI
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer

早期对转移性激素敏感型前列腺癌的 prostate-specific antigen (PSA) 阳性反应预测

2025-12-170
OAAI
ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI)

ESMO对基于AI的肿瘤学生物标志物的基本要求 (EBAI)

2025-11-180
OAAI
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer

循环肿瘤DNA中的致病基因组改变可预测转移性去势抵抗性前列腺癌患者的总生存期

2025-08-060
PREAI
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer

放疗与手术为基础的治疗策略在高风险前列腺癌中的比较

2025-07-190
PRE
Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

阿法替尼在具有神经营养因子1(NRG1)融合的实体瘤患者中的应用:Targeted Agent and Profiling Utilization Registry(TAPUR)研究中的病例系列

2025-05-010
PRE
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

ESMO肿瘤不可知分类器和筛选器 (etac-s): 一种评估分子引导疗法的肿瘤不可知潜力和指导药物开发的工具

2024-11-012
OAAI
Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes

雄激素产生,摄取和转化 (APUC) 基因定义了具有不同临床结果的前列腺癌患者

2024-10-221
OA
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing

适应社会生态模型以解决黑人参与前列腺癌基因检测的差异

2024-09-180
OAAI